4//SEC Filing
RAYNOR DANIEL 4
Accession 0001144204-18-015633
CIK 0001023024other
Filed
Mar 18, 8:00 PM ET
Accepted
Mar 19, 4:54 PM ET
Size
7.4 KB
Accession
0001144204-18-015633
Insider Transaction Report
Form 4
RAYNOR DANIEL
Director
Transactions
- Sale
Common Stock
2018-03-15$61.50/sh−1,902$116,973→ 294,316 total(indirect: See Footnote) - Sale
Common Stock
2018-03-19$60.62/sh−5,313$322,074→ 289,003 total(indirect: See Footnote)
Footnotes (3)
- [F1]This transaction was executed in multiple trades at prices ranging from $61.00 to $62.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F2]Held by Argentum Capital Partners II. L.P., which the Reporting Person may be deemed to be a beneficial owner pursuant to rule 16a-1(a)(1).
- [F3]This transaction was executed in multiple trades at prices ranging from $60.50 to $60.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Documents
Issuer
ANI PHARMACEUTICALS INC
CIK 0001023024
Entity typeother
Related Parties
1- filerCIK 0001068854
Filing Metadata
- Form type
- 4
- Filed
- Mar 18, 8:00 PM ET
- Accepted
- Mar 19, 4:54 PM ET
- Size
- 7.4 KB